Recognizing and managing comorbidities in psoriatic arthriti... : Current Opinion in
Rheumatology Recognizing and managing comorbidities in psoriatic arthritis : Current …

Psoriatic arthritis (PsA) is well known to affect the skin and joints and emerging research has
identified specific comorbidities related to PsA. More than half of patients with PsA have at …

Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and
dietary supplements) presents with a range of both phenotypes and severity, from acute …

Background Etanercept plus methotrexate combination therapy has not been adequately
investigated in psoriasis. Objectives To evaluate etanercept plus methotrexate vs …

Objectives. To identify all of the patients affected by chronic hepatitis C infection treated with
TNF-α blockers (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab) in …

Background Patients with psoriatic disease may be more susceptible to methotrexate
hepatotoxicity than those with rheumatoid arthritis (RA); however, direct evidence supporting …

Objective Methotrexate is an effective treatment for a variety of inflammatory diseases.
Robust evidence on the risk of serious liver injury is lacking. The aim of this study was to …

BACKGROUND & AIMS: Although methotrexate (MTX) is used in the effective treatment of
inflammatory disorders, its use is hampered by the risk of liver fibrosis. Non-invasive …

Epidemiological studies have shown that patients with psoriatic arthritis (PsA) are often
affected by numerous comorbidities that carry significant morbidity and mortality. Reported …

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …